The biggest obstacle holding back the entire RNA field, including mRNA and oligonucleotides, is the challenge of delivering these therapies beyond the liver. A breakthrough in novel delivery mechanisms is considered more critical for unlocking the modality's therapeutic potential than discovering new RNA molecules.

The next breakthrough in RNA therapeutics won't come from a single innovation. It requires combining two key elements: a 'programmable' mRNA payload designed to be active only in specific cells, and a targeted delivery system to get it there. This two-part solution represents the next generation of in-vivo therapies.

To move beyond rare diseases, gene therapy must evolve. Key industry trends include lowering doses to mitigate toxicity, developing technologies to overcome neutralizing antibodies for re-dosing, and eliminating complex immunosuppression regimens. This evolution will enable treatment in community or outpatient settings, which is crucial for scaling to larger patient populations.

In the competitive Alpha-1 antitrypsin deficiency space, Prime Medicine's strategy is to offer a best-in-class solution. Their prime editing approach permanently corrects the mutation, allowing the body's natural systems ("endogenous control") to regulate the production of fully functional "wild-type" protein, a key differentiator from other therapies.

CEO Greg Verdine articulates two problems: a specific one (safer organ transplant drugs) and a general one he's pursued for 25 years (drugging "undruggable" targets). This dual framing anchors the company in an immediate market while showcasing a massive, long-term platform vision for investors and partners.

Eupraxia's technology is defined by its precision: delivering a stable, flat dose directly into target tissue for up to a year. This hyper-local approach mimics the stability of a continuous IV infusion, aiming to maximize efficacy while minimizing systemic side effects caused by the 'peaks and troughs' of conventional pills or injections.

While current RNAi therapies are successful, they almost exclusively target liver cells (hepatocytes). The industry is only at the beginning of its journey. The real, massive opportunity lies in cracking the delivery challenge to target other cells, tissues, and organs with unmet medical needs.

Resvita's CTO joined because the company first solved the difficult challenge of delivering proteins to the skin. This created a 'plug-and-play' platform that he calls a 'protein designer's dream.' By abstracting away the delivery problem, the team can focus solely on designing the optimal therapeutic protein for each disease.

For 30 years, the advancement of intravenous genetic medicine has been stalled because therapies naturally accumulate in the liver, limiting treatment to that one organ. The true revolution begins with developing medicines that can be administered into the bloodstream and successfully target other organs throughout the body.